Research into the treatment, known as chimeric antigen receptor T-cell therapy (CAR T-cell), shows it is more effective than current cancer treatments, but effectiveness does not imply value as far as health budgets are concerned. Australian and US blood cancer specialists reviewed the current measures of cost effectiveness and identified multiple strategies that could be put in place to reduce the overall cost of treatment, update value assessments or improve...

Forty per cent of patients with the most common form of aggressive non-Hodgkin lymphoma (diffuse large B-cell lymphoma) either relapse or are refractory to...

We are very proud to announce that the Snowdome Foundation has earned a place in the High-Growth Companies Asia-Pacific 2021 ranking. The ranking assesses...